Log in to save to my catalogue

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2299449148

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Colorectal cancers with
BRAF
mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a response rate of 26% and a median overall survival of 9 months.

Alternative Titles

Full title

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2299449148

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2299449148

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1908075

How to access this item